REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
REGENERON PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$782.04−8.70 (-1.10%)
Close on Oct 19, 2026
- Market cap
- $82.90B
- P/E (TTM)
- 19.3
- Dividend yield
- –
REGENERON PHARMACEUTICALS, INC. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration revenue | $2.46B | $1.90B | $1.97B | $1.97B | $1.86B | $1.53B | $1.61B | $1.66B | $1.52B | $1.27B | $1.37B | $1.44B | 57.2% | +31.9% |
| Net product sales | $1.64B | $1.53B | $1.67B | $1.59B | $1.63B | $1.42B | $2.00B | $1.95B | $1.92B | $1.76B | $1.85B | $1.79B | 38.3% | +0.7% |
| Libtayo | $489.40M | $438.20M | $425.40M | $365.20M | $376.50M | $285.10M | $366.90M | $288.60M | $297.40M | $263.90M | $243.80M | $232.40M | 11.4% | +30.0% |
| Other revenue | $193.30M | $171.20M | $238.60M | $198.20M | $183.90M | $81.90M | $179.40M | $114.20M | $104.50M | $116.90M | $212.50M | $138.30M | 4.5% | +5.1% |
| Lynozyfic | $16.50M | $11.20M | – | – | $0 | $0 | – | – | – | – | – | – | 0.4% | – |
| Other products | $0 | $31.30M | $9.30M | $800.00K | $0 | $0 | $0 | $0 | – | – | – | – | 0.0% | – |
| Inmazeb | – | – | – | – | – | – | – | $35.60M | $0 | $1.00M | – | $3.30M | – | – |
By region
From the segment and revenue-disaggregation notes of Regeneron Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.